Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor.
G-CSF
absolute monocyte count
absolute neutrophil count
chemotherapy
febrile neutropenia
granulocyte colony-stimulating factor
monocytopenia
Journal
Therapeutics and clinical risk management
ISSN: 1176-6336
Titre abrégé: Ther Clin Risk Manag
Pays: New Zealand
ID NLM: 101253281
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
05
2021
accepted:
21
07
2021
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
16
9
2021
Statut:
epublish
Résumé
Chemotherapy-induced febrile neutropenia is a common and serious oncological emergency which carries a substantial mortality and morbidity. The main objective of this study is to evaluate the usage of absolute monocyte count (AMC) at presentation as a prognostic factor for patients with chemotherapy-induced febrile neutropenia who were subsequently treated with granulocyte colony-stimulating factor (G-CSF). The electronic medical records of our center were used retrospectively to identify patients diagnosed with unprecedented chemotherapy-induced febrile neutropenia treated with G-CSF between January 2010 to December 2020 and diagnosed with solid and hematological malignancies. Patient's demographics, disease characteristics and laboratory investigations were extracted. Disease progression measures were statistically compared between the study groups in the short-term period of follow-up (six days) including absolute neutrophil count (ANC), ANC difference compared to the baseline readings, hospitalization period, and mortality. A total of 80 patients were identified and categorized into two groups namely monocytopenia (n = 34) and non-monocytopenia (n = 46) with an AMC cutoff point of 0.1×10 Monocytopenia holds a worse prognosis in chemotherapy-induced febrile neutropenia patients treated with G-CSF. In addition, AMC values at presentation represents a potential risk factor that can predict short-term changes regarding ANC measures.
Identifiants
pubmed: 34522100
doi: 10.2147/TCRM.S318370
pii: 318370
pmc: PMC8435033
doi:
Types de publication
Journal Article
Langues
eng
Pagination
963-973Informations de copyright
© 2021 Alshari et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest for this work.
Références
Eur J Clin Microbiol Infect Dis. 2013 Jan;32(1):101-5
pubmed: 22895891
Arch Intern Med. 2011 Sep 12;171(16):1502-3
pubmed: 21911638
J Oncol Pract. 2015 Jan;11(1):47-54
pubmed: 25491042
P T. 2018 Apr;43(4):228-232
pubmed: 29622943
Int J Mol Med. 1998 Jun;1(6):943-51
pubmed: 9852629
Oncol Lett. 2012 Apr 1;3(4):860-864
pubmed: 22741007
Leuk Lymphoma. 2003 Dec;44(12):2069-76
pubmed: 14959849
Eur J Haematol. 1992 Oct;49(4):199-207
pubmed: 1281454
Ann Oncol. 2016 Sep;27(suppl 5):v111-v118
pubmed: 27664247
Sci Rep. 2019 Sep 10;9(1):12937
pubmed: 31506515
Br J Cancer. 2011 Aug 23;105(5):612-7
pubmed: 21811253
Immunopharmacology. 1995 Mar;29(2):111-9
pubmed: 7539779
J Clin Oncol. 2018 May 10;36(14):1443-1453
pubmed: 29461916
Br J Haematol. 2014 Nov;167(4):441-52
pubmed: 25196917
Support Care Cancer. 2020 Mar;28(3):1289-1294
pubmed: 31240465
Clin Infect Dis. 2011 Feb 15;52(4):e56-93
pubmed: 21258094
J Oncol Pharm Pract. 2014 Jun;20(3):190-8
pubmed: 23824496
Oncotarget. 2018 Apr 10;9(27):18970-18984
pubmed: 29721176
Br J Cancer. 2016 May 24;114(11):1191-8
pubmed: 27187687
Exp Hematol. 2002 Oct;30(10):1115-23
pubmed: 12384141
J Clin Oncol. 2005 Jun 20;23(18):4198-214
pubmed: 15961767
Biol Blood Marrow Transplant. 2018 Nov;24(11):2293-2301
pubmed: 29777867
Br J Haematol. 2009 Mar;144(5):677-85
pubmed: 19055662
Ann Emerg Med. 2017 Jun;69(6):755-764
pubmed: 28041827
J Exp Med. 2011 Feb 14;208(2):251-60
pubmed: 21282380
Breast Cancer Res Treat. 2012 Apr;132(3):947-53
pubmed: 21706156
Crit Rev Oncol Hematol. 2020 May;149:102922
pubmed: 32244162
Clin Cornerstone. 2006;8 Suppl 5:S5-11
pubmed: 17379162
Microbiol Mol Biol Rev. 2018 Feb 7;82(1):
pubmed: 29436479
Cytokine Growth Factor Rev. 2014 Aug;25(4):355-67
pubmed: 25131807
Cancer. 1981 Feb 15;47(4):801-5
pubmed: 7226028
J Clin Oncol. 2000 Aug;18(16):3038-51
pubmed: 10944139
Cochrane Database Syst Rev. 2014 Oct 30;(10):CD003039
pubmed: 25356786
Ann Oncol. 2009 Mar;20(3):513-9
pubmed: 19139177
Mol Med Rep. 2014 Nov;10(5):2389-94
pubmed: 25231117
J Clin Oncol. 2015 Feb 10;33(5):465-71
pubmed: 25559804
Support Cancer Ther. 2005 Oct 1;3(1):36-46
pubmed: 18632435
Crit Rev Oncol Hematol. 2014 Jun;90(3):190-9
pubmed: 24434034
Cancer. 2003 Dec 1;98(11):2402-9
pubmed: 14635075
J Immunol. 2005 Dec 1;175(11):7085-91
pubmed: 16301609
Emerg Med Clin North Am. 2009 May;27(2):311-31
pubmed: 19447314
Blood. 1997 Jan 15;89(2):577-82
pubmed: 9002961
Semin Arthritis Rheum. 2009 Apr;38(5):389-95
pubmed: 18378278
J Cancer Res Ther. 2018 Sep;14(Supplement):S565-S570
pubmed: 30249869
Pediatr Hematol Oncol. 2006 Mar;23(2):143-51
pubmed: 16651243
Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S7-S10
pubmed: 15250014
J Clin Oncol. 2010 Jul 10;28(20):3227-33
pubmed: 20530282
Clin Respir J. 2017 Jul;11(4):453-458
pubmed: 26260239